



A Real-World Observational Study on Diabetes Mellitus Patients Administering Dual Combination Therapy of Teneligliptin and Metformin to Evaluate Renal Function

Shehla S et.al; Women's Med Clg. 2024; vol6.no2; 37-41

- ADMIRE study was to evaluate the renal function (serum creatinine and estimated Glomerular Filtration Rate (eGFR)) of the patients who were receiving teneligliptin and metformin combination therapy for T2DM in a real-world setting.
- Patients aged ≥ 18 to ≤ 85 years with uncontrolled T2DM (HbA1c ≥ 7.0 %) and eGFR of 60 mL/min/1.73m² receiving combination therapy of teneligliptin and metformin were included in the trial.
- 15,321 subjects enrolled in the study renal parameters were available for 1019 patients which were analyzed for the study objective (N=1019).
- A significant reduction was observed in (mean) serum creatinine (by 0.6 mg/dl), FPG (by 36.77 mg/dL), PPG (by 66.79 mg/dL), HbA1c (by 1.07%).

ADMIRE study showed that the introduction of combination therapy with metformin and teneligliptin significantly improves the renal profile and glycemic control in the Indian population with uncontrolled DM in real-world settings; demonstrating that it is safe and effective.

